HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) shares crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $16.15 and traded as low as $14.87. HUTCHMED shares last traded at $15.01, with a volume of 37,665 shares traded.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut HUTCHMED from a "buy" rating to a "hold" rating in a research report on Monday, November 18th.
Get Our Latest Report on HUTCHMED
HUTCHMED Price Performance
The stock's 50-day simple moving average is $16.06 and its two-hundred day simple moving average is $17.71. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.
Institutional Investors Weigh In On HUTCHMED
Hedge funds have recently modified their holdings of the business. Jane Street Group LLC raised its position in shares of HUTCHMED by 362.2% during the third quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock valued at $1,305,000 after buying an additional 49,366 shares during the last quarter. State Street Corp raised its stake in shares of HUTCHMED by 0.9% in the third quarter. State Street Corp now owns 349,524 shares of the company's stock valued at $6,826,000 after purchasing an additional 3,078 shares in the last quarter. Rhumbline Advisers lifted its position in HUTCHMED by 8.1% in the second quarter. Rhumbline Advisers now owns 7,553 shares of the company's stock worth $129,000 after purchasing an additional 564 shares during the period. M&G PLC increased its holdings in HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company's stock valued at $5,345,000 after buying an additional 132,333 shares during the period. Finally, Blue Trust Inc. raised its stake in shares of HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock valued at $69,000 after buying an additional 3,057 shares in the last quarter. 8.82% of the stock is owned by institutional investors.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
